Volume 23 Number 1 June 2007 23 1 2007 8 1 40 HPV HPV HPV 50 15 1 80-85%
1. 71,862 Globocan 2002 <87.3 <32.6 <26.2 <16.2 <9.3/100,000 Ferlay et al. 2 14,670 59,931 78,897 265,884 HPV 23, 25 HPV HPV 40-50 2, 6, 26-30 2 HPV HPV 14 HPV 2 1-3, 5, 6, 9-12 HPV HPV 100 HPV HPV HPV DNA HPV HPV HPV 13-15 630 13 13 13, 16 HPV HPV 70% 40% HPV-16 HPV-18 HPV 50%- HPV-45 HPV-31 HPV 80% 4% HPV 17, 18 HPV 10, 13, 14, 23, 31, 32 30 HPV HPV 25 40 45 19-22 22, 23 HPV HPV HPV5%-10%
HPV 70% HPV 32, 33 Pap HPV DNA 34, 35 10 2 50 60 70-80% 9, 39-41 5 1 5 75% 1. 1-8 490,000 270,000 85% 75,000 2050 100 HPV HPV 1% 42, 43 3, 42-48 20, 35 40, 42, 49 PATH, Molly Mort 3
4 2. 100,000 40, 42, 49 40 45 40 35 30 25 20 15 10 5 0 VIA - - Ferlay et al. 2 VIA VIA 3%~5% VIA VIA HPV DNA HPV DNA VIA VIA VIA 26, 48, 49-52 VILI VILI VIA VILI VILI 42, 48, 50, 51 LAMS 11,834 VIA VILI 2 52 VILI VILI HPV DNA HPV DNA HPV DNA 53 14 HPV DNA 30 30HPV 18, 53-58 2 hc2 2 HPV DNA ( Digene HPV hc2 13HPV 6~8
42, 59, 60 FastHPV 64-67 FastHPV 14 HPV DNA 2 2 100% 2007 FastHPV 2008 LEEP 27, 61, 62 1 19mm 59, 60 FastHPV hc2 100%LEEP HPV DNA HPV 27 9, 27, 42, 49, 61, 68, 69 5 HPV DNA 63 1A 92% 9 VIA 20, 27, 35 1. 85% LEEP 90%-98% 5-10 90%-94%
2. 1999 ACCP 36-38 2007 4 ACCP 1. 30 40 2. 3. HPV DNA VIA VIA * 4. HPV DNA 5. 85% 6 6. HPV 7. 8. 9. 10. HPV * HPV DNA VIA 20, 27 20, 70 2006 6 HPV Merck's Gardasil 2007 4 70 Gardasil HPV 1618
70% HPV HPV 611 90% 6 3 0.5ml 2 1 2 3 1 6 71 GlaxoSmith- Kline's Cervarix TM, HPV 16 18 3 0.5ml 2 3 1 6 2007 71 2 HPV 95% 16 18 100% 50% 71% 73-77 30 73-80 / - catch-up program 26 71, 72 HPV 35, 81 20 HPV HPV16 18 HPV HPV 7, 71, 72 2. HPV Gardasil (Merck) HPV 6, 11, 16, 18 0-, 2-, 6-0.5ml 70 25,000 15-26 100% b : 5 16 18 HPV 30 30 20, 81-84 HPV HPV HPV 85, 86 Cervarix TM (GlaxoSmithKline) 16, 18 a Baculovirus ASO4( A) 0-, 1-, 6-0.5ml 2007 18,000 15-25 100% b : 5 a. Cervarix TM 45 31 HPV 3 b. HPV 7
55, 90 HPV 4 5 78 5 HPV HPV 3, 7 B HPV 87 DNA HPV HPV 12, 54, 92 HPV 45 31 HPV 8 7, 77, 78 3, 7, 91 HPV HPV HPV HPV HPV 5 12, 54, 93, 94 71, 72, 77, 88, 89 3 7, 86 HPV 7, 86 12, 45 HPV HPV 95
PATH 4 B HIV HPV PATH / HPV HPV HPV 7, 96 HPV 2007 2008 2009 2010 92, 97-102 HPV 98 HPV HPV 9 101 101 45, 50, 65, 103 HPV 96, 104, 105, 106 HPV HPV 12, 95
HPV 10 HPV RHO www.rho.org PATH www.path.org/cervicalcancer www.alliance-cxca.org www.iarc.fr/cervicalindex.php www.who.int/reproductive-health/ publications/cancers.html
11
ISSN:0737-3732 Outlook PATH PATH Outlook PATH Outlook PATH Outlook : Outlook Editor PATH 1455 NW Leary Way Seattle, WA 98107-5136 USA Phone 206.285.3500 Fax: 206.285.6619 Email outlook path.org Outlook www.path.org/publications/publications-areas-series RHOwww.rho.org Paul Blumenthal, MD, MPH, Johns Hopkins University, USA Linan Cheng, MD, International Peace Maternity and Child Health Hospital, China Lawrence Corey, MD, Fred Hutchinson Cancer Research Center, USA Horacio Croxatto, MD, Chilean Institute of Reproductive Medicine, Chile Peter J. Donaldson, PhD, Population Council, USA Judith A. Fortney, PhD, Family Health International, USA Mary Kawonga, MD, University of the Witwatersrand, South Africa Atiqur Rahman Khan, MD, Technical Assistance Inc., Bangladesh Roberto Rivera, MD, Family Health International, USA Pramilla Senanayake, MBBS, DTPH, PhD, Global Forum for Health Research, Sri Lanka and UK C. Johannes van Dam, MD, MS, Population Council, USA Diane Castilaw Scott Wittet Scott Wittet Beth Balderston Dr. Paul Blumenthal, Michele Burns, Dr. Eduardo Franco, Dr. Sue Goldie, Dr. Lindsay Edouard, Jane Hutchings, Jeanette Lim, Dr. Harshad Sanghvi, Dr. John Sellors, Dr. Jacqueline Sherris, and Dr. Vivien Tsu, Outlook 2007, Program for Appropriate Technology in Health PATH